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This study evaluated the efficiency, effectiveness, and racial disparities reduction potential of Screening Colonoscopies for People
Everywhere in South Carolina (SCOPE SC), a state-funded program for indigent persons aged 50–64 years (45–64 years for African
American (AA)) with a medical home in community health centers. Patients were referred to existing referral network providers,
and the centers were compensated for patient navigation. Data on procedures and patient demographics were analyzed. Of 782
individuals recruited (71.2% AA), 85% (665) completed the procedure (71.1% AA). The adenoma detection rate was 27.8% (males
34.6% and females 25.1%), advanced neoplasm rate 7.7% (including 3 cancers), cecum intubation rate 98.9%, inadequate bowel
preparation rate 7.9%, and adverse event rate 0.9%. All indicators met the national quality benchmarks. The adenoma rate of 26.0%
among AAs aged 45–49 years was similar to that of older Whites and AAs. We found that patient navigation and a medical home
setting resulted in a successful and high-quality screening program. The observed high adenoma rate among younger AAs calls for
more research with larger cohorts to evaluate the appropriateness of the current screening guidelines for AAs, given that they suffer
47% higher colorectal cancer mortality than Whites.

1. Introduction
There is wide variation across population subgroups in
cancer incidence, mortality, or both. Nationally in the United
States of America, African Americans (AAs) have ≈17%
higher colorectal cancer (CRC) incidence and ≈47% higher
mortality than Whites [1]. AAs also are diagnosed at younger
ages, on average and with later-stage disease, have a higher
incidence before the recommended screening age of 50 years,
and tend to have worse prognoses even after accounting for

other factors [2, 3]. These disparities tend to be much larger
in South Carolina (SC) than in the US average [4, 5].
The majority of CRCs in average-risk individuals arise
from the polyp-to-cancer pathway, which translates into an
opportunity to prevent cancers by removing polyps detected
through screening age-appropriate adults. Of all cancer
screening tests, colonoscopy is the most effective both for
early detection and, more importantly, for primary prevention of CRC because it enables removal of precancerous
polyps before they turn cancerous. Colonoscopy has some
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disadvantages, however. It requires specially trained physicians and is expensive and invasive, requiring a well-equipped
and well-staffed facility for safe, high-quality performance.
Consequently, health insurance remains a key determinant
of colonoscopy screening completion, which currently stands
at 19.1% among working-age uninsured adults in the 2010
National Health Interview Survey Data, compared to 56.7%
among those privately insured [6]. Despite many uninsured
individuals having primary care access through the ambulatory care safety net, mainly federally qualified health centers
(FQHC), the colonoscopy rate among this subgroup is low,
about 24% [7], because FQHCs cannot obtain adequate
volumes of charity colonoscopy care.
SC has the 16th highest percentage of uninsured adults in
the USA [8] and has a higher proportion of AA population
(30%) than the national average. The program, Screening
Colonoscopies for People Everywhere in South Carolina
(SCOPE SC), was designed to leverage the medical home
relationship of FQHCs with uninsured individuals. A sum of
$1 million was authorized by the South Carolina Legislature
for the Department of Health and Environmental Control
(SCDHEC) to cover screening colonoscopy of average-risk
established FQHC patients ≥50 years old (≥45 years for
AAs) with income ≤200% of poverty and without private or
Medicaid insurance. Based on studies showing that patient
navigation improves colonoscopy completion rates [9, 10],
the program asked participating FQHCs to use their existing
colonoscopy referral channels and funded patient navigation services to maximize screening completion and other
facilitation services. The SCDHEC program office organized
referrals and follow-up care for individuals who experienced
a complication or were diagnosed with cancer.
About 800 screening procedures were targeted, based
on an average cost of $1,000 each (covering provider reimbursement at Medicare rates, patient navigation, and program
evaluation). Provider reimbursements were contingent upon
reporting to the program, thus allowing for monitoring of
procedure quality and completeness. At the end of year 1,
SCDHEC assigned the program performance evaluation to
an external academic research team, the results of which are
presented in this paper.

2. Methods
Four FQHC sites participated in the SCOPE SC program,
having been identified based on elevated CRC incidence,
mortality, and late-stage CRC rates; resources and infrastructure; and a geographic distribution pattern providing
for statewide representation. The program was promoted
via direct notification of FQHC staff and outreach workers
through promotional materials (postcards and posters) and
by including the program on the American Cancer Society’s
toll-free telephone hotline. Eligible individuals included current FQHC patients with current SC residency, US citizenship
(established with the social security number), no health
insurance, income ≤200% of the federal poverty limit, age
eligible (50–64 years for Whites without a CRC family history,
45–49 years for Whites with CRC family history, and 45–64
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years for AAs regardless of family history), no gastrointestinal
symptoms, and not being up to date with CRC screening
per published guidelines (Figure 1). All beneficiaries were
referred to by their primary care physician at a participating
FQHC. If not a current FQHC patient, they were required
to enroll as patients for purposes of adequate care and
referral for complications, cancer diagnosis and/or follow-up
surveillance.
Each FQHC had at least one navigator dedicated to
the program. Eligible patients were identified by the primary physician and referred to the navigator for obtaining
preauthorization from SCDHEC program staff. The patient
then received a bowel preparation kit that included written
instructions, and the procedure was scheduled. Navigators
included FQHC nurses or administrative staff who routinely
interacted with patients. FQHCs were compensated for navigation, $25 for the initial referral and associated paperwork
and $75 for successful completion of the procedure. SCOPE
SC program staff provided one-on-one training to navigators
and FQHC staff administering the program. The training
consisted of several hours of instruction emphasizing the
importance of an adequate bowel preparation including
detailed instructions for patients, methods to help patients
plan for their procedure (e.g., obtaining transportation and
other care-related advice), and details on program administration, referrals, and other resources.
As a condition of reimbursement, participating FQHCs,
endoscopy clinics, FQHCs, and laboratory service providers
submitted standard forms on all eligible individuals referred
for colonoscopy. Data collected included demographic,
relevant family and personal medical history (submitted
by FQHCs), clinical procedure and polyp information
(by colonoscopy providers), and polyp histopathology features (by laboratory service providers). SCDHEC established a medical quality assurance committee consisting of
community-based, SCDHEC, and academic physicians that
monitored procedure quality throughout the year by periodically reviewing the clinical and pathology data for all cases
submitted by providers. When suboptimal outcomes were
identified (low polyp detection rate, poor bowel preparation
rate, or placing multiple polyps from different colorectal
segments in a single jar), potential causes were discussed
by the committee and feedback communicated to providers
through the SCOPE SC program manager.
The study sample consisted of year I data on all screening
colonoscopies provided during fiscal year 2009-10 (July 1
through June 30). The study team systematically reviewed the
data files compiled from the patient referral, screening, and
laboratory forms together against the original patient forms
for accuracy and entered missing/discrepant data. Data entry
was completed onsite within the SCDHEC data system. Files
were linked, deidentified, and extracted in Excel format into
University of South Carolina (USC) computers. The study
was approved by the USC and SCDHEC Institutional Review
Boards.
Univariate statistics (and chi-square tests where applicable) are used to present the program’s efficiency (in outreach
and procedure completion), beneficiary demographics, disparity populations reached, procedure effectiveness (cecum
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Figure 1: SCOPE SC program organization chart.

intubation, polyp detection and retrieval, adenoma, advanced
neoplasm, and cancer detection rates), bowel preparation
quality, and patient safety (adverse event rate). SAS version
9.2 was used.

3. Results
Table 1 summarizes the SCOPE SC year 1 program performance on efficiency, effectiveness, and patient safety. Of
782 eligible beneficiaries identified by the four participating
FQHCs, 665 (85%) completed the procedure. The unadjusted
cecum intubation rate was 98.1% (the US Multisociety Task
Force (USMSTF), adjusted cecal intubation rate was 98.6%,
excluding unintubated cases due to poor bowel preparation)
[11], and the circumstance-adjusted cecum intubation rate
was 98.9% (excluding unintubated cases due to poor bowel

preparation and medical reasons requiring procedure termination) [12]. All rates, including the unadjusted rate, exceeded
the USMSTF benchmark of 95% [11].
The polyp detection rate was 56.4% (proportion of
screened persons with ≥1 polyp detected). The adenoma
detection rate (having any polyp with an adenomatous or
carcinomatous histology, excluding hyperplastic polyps and
normoplastic or lymphoid tissue) was 27.8% overall, 34.6%
for men and 25.1% for women. Both rates exceed the USMSTF
minimum standards of >25% for men and >15% for women
[11]. The advanced neoplasm detection rate (adenomas
≥ 10 mm, villous/tubulovillous adenomas, high-grade dysplasia, or cancer) was 7.7% overall, 9.9% in men and 6.8%
among women. Three cancer cases were found, 0.4% of those
were screened. No benchmark exists for advanced neoplasm
detection [11], although the USMSTF notes a documented
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Table 1: SCOPE SC program performance in year 1: efficiency of patient recruitment, effectiveness of procedure performance, and patient
safety.
Performance indicator
Program efficiency
Program target number of colonoscopy screenings (funding available)
Number of eligible beneficiaries identified
Number of who completed colonoscopy
% of eligible beneficiaries navigated through procedure completion
Number of performing physicians
Bowel preparation status documented (benchmark 100%) [12]
Patient safety: adverse event rate (benchmark 2%, all event types) [12]
Procedure performance quality
Cecal intubation rate (benchmark 95%) [12]
Bowel preparation status rated fair, good, or excellent
Proportion of screened persons with polyp(s)
Proportion of polyps completely removed
Proportion of polyps retrieved for pathology exam (benchmark 95%) [11]
Polyp, adenoma, and cancer detection
Proportion of screened persons with polyp(s)
Proportion of screened persons with hyperplastic polyp(s)
Proportion of screened persons with adenoma(s) found (ADR) (benchmark 15% for women and 25% for men) [12]
Proportion with advanced neoplasm removed (cancer and polyps at imminent risk of cancer)
Diagnosed with colorectal cancer
Total number of polyps removed
Total number of adenomas removed
Total number of advanced neoplasms removed

Number/%
800
782
665
85%
32
98.5%
0.9%∗
98.9%
92.1%
56.4%
93.1%∗∗
99.9%
56.4%∗∗
34.6%∗∗
27.8%
7.7%∗∗
3 (0.45%)
917
338
58

Advanced neoplasms include adenomas ≥10 mm in diameter, adenomas with villous or tubule villous features or high-grade dysplasia, and cancer or carcinoid
tumor.
∗
𝑛 = 6 (1) bleeding, (2) incomplete colonoscopy due to torsion, and (3) unspecified but having good bowel preparation and the procedure was completed, no
perforations.
∗∗
No national quality benchmarks exist for these indicators.

range of 3–10% [11] in US colonoscopy cohorts. The SCOPE
SC rate is close to the upper end of the documented range.
Adverse events were documented in 0.9% of procedures,
within the benchmark limit (𝑛 = 6 cases, (1) bleeding,
(2) incomplete colonoscopy due to torsion, and (3) unspecified but having good bowel preparation and the procedure was completed, no perforations). The USMSTF benchmarks are <1/300 case of sedation-related complications
requiring endotracheal intubation or mask ventilation, <1
bowel perforation per 1000 procedures, and <1/100 major
postpolypectomy bleeding [11]. Documentation of bowel
preparation status was available for 98.5% of recipients (655
out of 665), slightly lower than the benchmark of 100%
[11]. Bowel preparation status is important for maximizing
polyp detection [13, 14], and poor bowel preparation may
trigger cancellation of the procedure. Therefore adequate
bowel contributes to the cancer protection effectiveness of
colonoscopy [15]. Bowel preparation status was good or
excellent in 69.3%, fair in 22.7%, and poor in 7.9% of the
patients. The nationwide rate of poor preparation is 25% [14].
There are no USMSTF benchmarks for rates of good/poor
bowel preparation although a benchmark exists for the rate
of documentation of bowel preparation status (100%).

Of a total of 917 polyps found, 916 (99.9%) were retrieved
for pathological examination (benchmark 95%) [11]. A total
of 338 adenomas (including advanced neoplasms) were
removed among the 665 patients, for an average of 0.51
adenomas per subject screened. Of these, 58 (0.09 per
subject screened) were advanced neoplasms. There are no
benchmarks established for the mean number of adenomas
per screened subject. Three cancer cases were found at
colonoscopy, two cancers located in the rectum and one in
the sigmoid colon. Of 55 advanced adenomas, 76.4% were
10 mm or more in diameter, 16.4% had villous or tubulovillous
features, and 5.5% showed high grade dysplasia. Additionally,
there were 8 serrated adenomas. Among the 45–49-year-old
AAs, 6 had advanced adenomas.
Table 2 shows the demographic characteristics of beneficiaries, the adenoma rate, and advanced neoplasm rate
among the demographic subgroups. Most beneficiaries were
female (71.1%), African American (71.1%), and lived in the
Midlands region of SC (75.3%). The mean age was 55.2 (SD =
4.9) years, and majority (64.4%) were aged 50–59 years.
The adenoma detection rate among males was 34.6%, and
among females 25.1% (𝑃 = 0.01). The rate was 26.0% among
those 45–49 years old (all AA), 28.4% in the 50–59 year age
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Table 2: SCOPE SC beneficiary demographics and corresponding adenoma detection rates (𝑛 = 665).

Geographic region
Upstate
Midlands
Low country
Patients
Gender
Male
Female
Race∗
White
Black
Other
Age (years)∗∗
45–49∗∗∗
50–59
60–64
Family history
Yes
No or missing∗∗∗∗

Number of beneficiaries

Adenoma detection rate

Advanced neoplasm
detection rate

142 (21.5%)
501 (75.3%)
22 (3.3%)

38/141 (27.0%)
140/498 (28.1%)
6/22 (27.3%)

16/141 (11.3%)
33/498 (6.6%)
2/22 (9.1%)

192 (28.9%)
473 (71.1%)

66/191 (34.6%)
118/470 (25.1%)

19/191 (9.9%)
32/470 (6.8%)

164 (24.9%)
468 (71.1%)
26 (4.0%)

51/163 (31.3%)
123/465 (26.5%)
5/26 (19.2%)

17/163 (10.4%)
31/465 (6.7%)
2/26 (7.7%)

77 (11.6%)
426 (64.4%)
159 (24.0%)

20/77 (26%)
120/423 (28.4%)
43/158 (27.2%)

6/77 (7.8%)
35/423 (8.3%)
9/158 (5.7%)

85 (12.8%)
580 (87.2%)

25/85 (29.4%)
159/576 (27.6%)

9/85 (10.6%)
42/576 (7.3%)

Note: denominators for adenoma and advanced neoplasm detection rate vary due to missing data.
∗
Race information was missing for 7 patients.
∗∗
Age information was missing for 1 patient.
∗∗∗
Includes 14 Whites screened due to a family history of colorectal cancer.
∗∗∗∗
Question design did not permit distinction between absence of family history and nonresponse.

group, and 27.2% in the 60–64 age group (𝑃 = 0.89). When
examined by race, 31.3% of Whites, 26.5% of AAs, and 19.2%
of other race/ethnicities had ≥1 adenoma (𝑃 = 0.31). There
was no significant difference in adenoma rates by geographic
region. AAs aged 45–49 years were as likely as older Whites
and AAs (aged over 50 years) to have an adenoma after
controlling for gender (𝑃 = 0.56).
Table 3 presents the performance of SCOPE SC in
addressing racial disparities in CRC. Of screening-eligible
beneficiaries recruited at the FQHCs, 71.2% were AA. Among
those who completed colonoscopies, 71.1% were AA. The
adenoma detection and advanced neoplasm detection rates
are also presented.

4. Discussion
There is little documentation of state-funded CRC screening
programs for the indigent, particularly statewide programs
emphasizing colonoscopy as the primary screening test.
One study documented the program design and beneficiary
profile of Louisiana’s state-funded screening program that
offered fecal immunochemical testing (FIT) to the medically
indigent attending FQHCs followed by colonoscopy for those
with abnormal FIT tests [16]. The State of Delaware has
implemented a colonoscopy-based screening program for the
uninsured since 2002. Its performance and outcomes up to

2009 are documented [17]. By 2009 the program had wiped
out racial disparities in screening (74% of AAs and Whites
being up to date with CRC screening in the BRFSS 2009 data,
of which 85% was accounted for by colonoscopy screening
in both racial groups). Similar to the Delaware program the
SCOPE SC program chose to fund primary colonoscopy
screening in view of low (per test) sensitivity of FIT for
CRC prevention [18]. In the SC program 85% of 782 persons
who were recruited completed the screening colonoscopy
procedure compared to 66% of 975 persons recruited for the
FIT procedure in Louisiana, despite the significantly invasive
and therefore potentially intimidating nature of colonoscopy
relative to FIT.
The design and performance of the SCOPE SC program
in year 1 were consistent with the US Healthy People 2020 goal
of “health equity, elimination of disparities and improving the
health of all groups” by “facilitating high-quality, longer lives,
free of preventable disease, disability, injury and premature
death” [19]. The Healthy People 2010 goal of reducing CRC
mortality to 13.9/100,000 [19] remained far beyond reach
(current rate 21.9/100,000) [1], partly due to disproportionately high CRC mortality among AAs [20] (47% higher
than among Whites). In the SCOPE SC program 71% of
beneficiaries were AA, and the mean beneficiary age was
55.2 years. All of these features are encouraging. Considering
the potential for cumulative cancer mortality gain, the mean
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Table 3: SCOPE SC performance in addressing racial disparities in colorectal cancer.
Eligible beneficiaries
recruited

Percent completed
colonoscopy

Percent with adenomas
found

Percent with advanced
neoplasms

African American
White
Other/missing

493
172
117

468 (95.0%)
164 (95.3%)
33 (28.2%)

123 (26.3%)
51 (31.1%)
10 (30.3%)

31 (6.6%)
17 (10.4%)
3 (9.1%)

Total

782

665 (85.0%)

184 (27.7%)

51 (7.7%)

Race/ethnicity

beneficiary age was close to the recommended screening
commencement age of 50 years, indicating that SCOPE
SC gave the beneficiary cohort an early start for optimal
preventive benefit, with more potential life years saved than
would be the case if the mean age were higher. A high
proportion of AA among beneficiaries served (71% compared
to the state’s overall AA population of 29%) indicates that
SCOPE SC succeeded in focusing more resources on this
high-disparity group. Equal proportions of screening-eligible
AAs and Whites recruited actually completed the procedure.
Of the AA population in SC 51.3% live below 200% of poverty
compared to 31.4% of Whites [21]. The screening coverage
advantage that was achieved for AAs relative to Whites
is consistent with the performance of Delaware’s statewide
screening program for the medically indigent implemented
from 2002 to 2011. The Delaware program achieved a 100%
reduction in colonoscopy screening disparities between AAs
and Whites [17]. One study limitation is the lack of information on the reasons/barriers for completion of the procedure
among those who did not complete the procedure.
Almost 12% of beneficiaries were AAs aged 45–49 years.
Unexpectedly, we found that the adenoma rate and advanced
neoplasm rate in this age group were similar to the rates
found among older Whites and AA. A study limitation is
that potential recruitment bias favoring those with a family
history among younger AAs cannot be ruled out. Although
the patient referral form had a question on family history, the
design was such that nonresponse could not be distinguished
from those without a family history. However the frequency
of adenomas was not different among those with a family
history of CRC (Table 2).
Our finding suggests that SCOPE SC’s innovation of
extending coverage to AAs aged 45–49 years is justified and
is consistent with the American College of Gastroenterology
recommendations [22], earlier than the American Cancer
Society’s recommended screening age of 50 years uniformly
for all racial groups [23]. Currently almost no insurance
plan covers screening prior to 50 years of age. Our findings
emphasize the need for further research with larger cohorts
to verify the evidence for changing the screening eligibility
age for AAs. On another note, the preponderance of women
(71%) among SCOPE SC beneficiaries indicates that more
focused efforts to recruit males are needed.
Provider engagement and influence on patients’ decisions
to undergo elaborate colon preparation are facilitated by
an established doctor-patient relationship, usually not an
option for uninsured patients relying on episodic charity care
received from sporadically available providers in emergency

rooms and free clinics. Because FQHCs serve as a primary
care medical home for the uninsured, they present an opportune setting for colonoscopy screening programs targeting
the medically indigent. The SCOPE SC program chose to
deploy FQHCs as the patient recruiting sites and provided
funds to cover colonoscopy costs and patient navigation,
which yielded highly encouraging results: rapid accrual of
targeted beneficiaries, very high procedure completion rate
of 85.0%, and high rates of acceptable bowel preparation.
The critical role of patient navigation in improving bowel
preparation and adenoma detection is well documented
[24–26]. The procedure completion rate of 85% exceeds
the documented rate of 66% following structured patient
navigation efforts in New York City [9] and is similar to a
recently documented rate of 91% colonoscopy completion
following a comprehensive patient navigator program in New
York City [27].
Despite meeting or exceeding the USMSTF benchmark
rates for cecum intubation, polyp retrieval, and adenoma
detection, the cohort had a suboptimal bowel preparation
rate (considering fair and poor preparation) of 30.6%, which
is consistent with the 34% rate achieved in a Medicaid
primary care clientele in New York City by implementing
comprehensive patient navigation services [27]. The cohort’s
7.9% rate of poor bowel preparation (which causes cancellation of the procedure and sometimes termed as “inadequate
preparation” [27]) is much lower than the national average
of 25% [14]. The higher rate of adequate bowel preparation for the cohort is attributable, at least in part, to the
detailed data collection system coupled with ongoing quality
monitoring and feedback by an expert panel, instead of the
widely prevalent practice of after-the-fact program evaluation
typical of most programs. Three cancer cases were detected
and referred for treatment. All were asymptomatic patients.
Cancer stage information is not available.
In conclusion, year 1 of the SCOPE SC program served
as a successful pilot validation of the program’s innovative
design elements: leveraging the medical home relationships
of the uninsured with FQHCs, purposive funding of patient
navigation, and extending coverage to AA aged 45–49 years.
Results show that high completion rates can be achieved
within an ad hoc program’s fiscal year timeline. The program
design enabled scarce dollars to selectively reach out to
populations with the greatest need, thereby maximizing the
program’s potential contribution to the healthy people 2020
goal for reducing overall CRC mortality. Expansion of earmarked appropriations for colonoscopy screening of the
medically indigent in SC makes sound economic sense as
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the state and federal governments stand to reap Medicaid
and Medicare cost savings on CRC treatment in later years.
Appropriations should be linked to a structured quality management system via establishment of provider accountability
systems that track performance against quality indicators.
The relatively high rate of adenomas and advanced neoplasms among AAs aged 45–49 years is both intriguing and
potentially very important. Given the increased probability of
more aggressive disease at younger ages [28], this has major
implications for policy and practice aimed at reducing racial
disparities in CRC incidence and mortality. This result calls
for further investigation with larger screening cohorts.
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